Results — RR/ARR/NNT & Individualized

Study Summary

Title: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Authors: Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F et al.

Journal: New England Journal of Medicine

Year: 2022

Publisher: Massachusetts Medical Society

DOI: 10.1056/NEJMoa2206286

2×3 Table

	Hospitalization	No Hospitalization	Total
Exposed (Treatment: Dapaglifozin)	329	2802	3131
Unexposed (Control: Placebo)	418	2714	3132

Section 1 — Computation based on Journal

Risk (Exposed): 0.105

Risk (Unexposed): 0.133

Risk Ratio (RR): 0.787

Absolute Risk Reduction (ARR = Ru − Re): 0.028

NNT: 36

NNH (if harm): —

Interpretation: For every 36 treated with Dapaglifozin, you can prevent one Hospitalization.

Notes: ARR uses Ru − Re. NNT/NNH uses ceil(1/|ARR|). If a denominator is zero, that metric is “—”.

Section 2 — Individualizing Results

Baseline Risk (Control): 0.100

Study RR: 0.787

Estimated Treated Risk: 0.079

Individualized ARR: 0.021

Individualized Interpretation: For every 48 like your patient (baseline risk 0.100) treated with Dapaglifozin, one Hospitalization may be prevented.

Method: Treated Risk_individual = BaselineRisk × RR; Individualized ARR = BaselineRisk − TreatedRisk_individual.